4569
KYORIN Pharmaceutical Co.,Ltd.
杏林製薬
- Industry
- Pharmaceutical
- Market
- Prime
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Mar 2022
105,534
Mar 2023
113,270
Mar 2024
119,532
Mar 2025
130,087
Mar 2026
126,257
Operating profit(million JPY)
Mar 2022
5,007
Mar 2023
5,123
Mar 2024
6,013
Mar 2025
12,567
Mar 2026
3,567
Operating profit margin(%)
Mar 2022
4.74
Mar 2023
4.52
Mar 2024
5.03
Mar 2025
9.66
Mar 2026
2.83
Profit before tax(million JPY)
Mar 2022
5,216
Mar 2023
6,906
Mar 2024
7,019
Mar 2025
12,770
Mar 2026
4,451
Profit(million JPY)
Mar 2022
3,932
Mar 2023
4,723
Mar 2024
5,322
Mar 2025
9,086
Mar 2026
3,448
Total assets(million JPY)
Mar 2022
171,924
Mar 2023
176,045
Mar 2024
177,679
Mar 2025
193,618
Mar 2026
195,455
Cash and cash equivalents(million JPY)
Mar 2022
26,289
Mar 2023
18,816
Mar 2024
13,886
Mar 2025
15,021
Mar 2026
11,802
Cash flows from operating activities(million JPY)
Mar 2022
6,346
Mar 2023
2,008
Mar 2024
1,549
Mar 2025
3,506
Mar 2026
6,381
Cash flows from investing activities(million JPY)
Mar 2022
-2,560
Mar 2023
-6,275
Mar 2024
-3,187
Mar 2025
-6,323
Mar 2026
-1,644
Cash flows from financing activities(million JPY)
Mar 2022
-4,112
Mar 2023
-3,363
Mar 2024
-3,347
Mar 2025
3,952
Mar 2026
-7,956
Return on equity(%)
Mar 2022
3.2
Mar 2023
3.8
Mar 2024
4.2
Mar 2025
6.8
Mar 2026
2.5
Equity ratio(%)
Mar 2022
72.4
Mar 2023
71.3
Mar 2024
73.6
Mar 2025
70.4
Mar 2026
72.9
Earnings per share(JPY per share)
Mar 2022
68.62
Mar 2023
82.44
Mar 2024
92.74
Mar 2025
158.17
Mar 2026
60.03
Net assets per share(JPY per share)
Mar 2022
2,172.83
Mar 2023
2,189.4
Mar 2024
2,276.52
Mar 2025
2,372.29
Mar 2026
2,479.28
Dividend per share(JPY per share)
Mar 2022
52
Mar 2023
52
Mar 2024
52
Mar 2025
57
Mar 2026
57
Payout ratio(%)
Mar 2022
75.78
Mar 2023
63.08
Mar 2024
56.07
Mar 2025
36.04
Mar 2026
94.95
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.